5 unchanged sentences
Not Applicable.
−Removed: Table of Content s
Executive Officers of the Registrant (ages as of February 1, 2026)
7 unchanged sentences
63 Executive Vice President and President, Merck Animal Health (since September 2011)
−Removed: Cristal Downing 56 Executive Vice President and Chief Communications & Public Affairs Officer (since August 2021);
−Removed: Prior to that, Vice President Medical Devices, Global Communications and Public Affairs Johnson & Johnson (December 2020-August 2021);
−Removed: Vice President Financial Communication, Johnson & Johnson (January 2018-December 2020)
Chirfi Guindo 60 Senior Vice President, Chief Marketing Officer, Human Health (since July 2022);
5 unchanged sentences
Dean Li 63 Executive Vice President, President, Merck Research Laboratories (since January 2021)
−Removed: Senior Vice President, Discovery Sciences and Translational Medicine, Merck Research Laboratories (November 2017-January 2021)
Caroline Litchfield 57 Executive Vice President and Chief Financial Officer (since April 2021)
−Removed: Senior Vice President, Corporate Treasurer (January 2018-March 2021)
58 Senior Vice President and President Merck U.S.
1 unchanged sentence
Senior Vice President and Head of Global Oncology Commercial (January 2021-December 2021)
−Removed: Senior Vice President and President of MSD K.K.
−Removed: (July 2016-December 2020)
Joseph Romanelli 52 Senior Vice President and President MSD International Human Health (since July 2022);
5 unchanged sentences
Williams 57 Executive Vice President, Chief Information and Digital Officer (since August 2020)
−Removed: Acting Chief Information and Digital Officer (December 2019-August 2020)
Jennifer Zachary 48 Executive Vice President and General Counsel (since April 2018)
−Removed: Table of Content s
+Added: On February 2, 2026, the Company announced that Sanat Chattopadhyay, Executive Vice President and President, Merck Manufacturing Division, will retire from the Company, effective July 1, 2026.
+Added: The Company announced that Mr.
+Added: Maraldo will assume the role as Executive Vice President and President, Merck Manufacturing Division, effective May 1, 2026, at which time Mr.
+Added: Maraldo will become, and Mr.
+Added: Chattopadhyay will cease to be, an Executive Officer of the Company.
+Added: Chattopadhyay will remain in a strategic advisory role at the Company until his retirement.
+Added: 49 Senior Vice President, Human Health Operations (since June 2025), Senior Vice President, Global Biologic Operations (February 2022 – June 2025), Vice President, Large Molecule Commercialization (June 2020 – February 2022)
+Added: On February 12, 2026, the Company announced that Joseph Romanelli has decided to retire from the Company in the second quarter of 2026.
+Added: On February 23, 2026, the Company announced that Brian Foard will join the Company as Executive Vice President, and President Specialty, Pharma & Infectious Diseases, effective March 2, 2026.
+Added: Foard most recently served as Executive Vice President and Head of Specialty Care at Sanofi.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.